RxDoctor Payments Data

Brett Victor, MD

Cardiovascular Disease · Philadelphia, PANPI 1285897173

Payments from drug & device makers

$41,265in general payments, 2019–2025

Across 83 payments — averaging $497.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$39K
  • Johnson & Johnson$357
  • Atricure, Inc.$228
  • Impulse Dynamics (USA) Inc.$190
  • Amgen$184
  • Boehringer Ingelheim$135
  • plus $741 from 15 others

What the payments were for

  • Speaking & faculty fees$36,54189%
  • Travel & lodging$1,8695%
  • Food & beverage$2,8547%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,265 in reported general payments places this provider in the 85th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$586,204
Medicare patients
955
Services billed
3,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban192$183,809
EntrestoSacubitril/Valsartan74$71,463
XareltoRivaroxaban61$63,256
Repatha SureclickEvolocumab70$54,991
JardianceEmpagliflozin32$29,542
TrulicityDulaglutide20$19,226
Praluent PenAlirocumab26$18,301
VascepaIcosapent Ethyl25$12,364
Atorvastatin Calcium282$4,528
Ezetimibe99$3,672
Ranolazine ErRanolazine27$2,772
Metoprolol Succinate180$2,730
Rosuvastatin Calcium143$2,327
Carvedilol146$1,223
Amlodipine Besylate168$1,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$25$71,46374 claims
Johnson & JohnsonXarelto$357$63,25661 claims
Boehringer IngelheimJardiance$135$29,54232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →